Literature DB >> 725539

Clinical and laboratory manifestations in patients with serological evidence of Mycoplasma pneumoniae infection.

A Pönkä.   

Abstract

139 cases of Mycoplasma pneumoniae infection (serological diagnosis) were treated at Aurora Hospital, Helsinki, between January 1975 and August 1977. In 123 patients the main diagnosis was respiratory infection; 114 of these had pneumonia. The frequency of complications was high: 8 patients had neurologic, 6 cardiac and 5 joint symptoms. Although a significant rise in titre of complement-fixing antibodies to M. pneumoniae was required, the low titre level in some patients who had manifestations less frequently associated with M. pneumoniae infection may suggest nonspecific reactions. Nearly half of the patients in this study had plasmocytosis in the peripheral blood suggesting a strong antibody response. This might be connected with some serological reactions detected in association with M. pneumoniae infections.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 725539     DOI: 10.3109/inf.1978.10.issue-4.03

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  Neurological illness associated with Mycoplasma pneumoniae infection: a study of eight cases.

Authors:  J H Connolly; S A Hawkins
Journal:  Ir J Med Sci       Date:  1980-03       Impact factor: 1.568

Review 2.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.

Authors:  Svitlana Demyanets; Alexandra Kaider; Ingrid Simonitsch-Klupp; Günther Bayer; Almira Subasic; Renate Thalhammer; Harald Esterbauer; Maria T Krauth; Hermine Agis; Thomas Reiter; Ilse Schwarzinger
Journal:  Ann Hematol       Date:  2020-09-15       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.